Investigational Drug Information for Plinabulin
✉ Email this page to a colleague
What is the development status for investigational drug Plinabulin?
Plinabulin is an investigational drug.
There have been 12 clinical trials for Plinabulin.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neutropenia. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.
There are thirty US patents protecting this investigational drug and two hundred and fifty-four international patents.
Summary for Plinabulin
| US Patents | 30 |
| International Patents | 254 |
| US Patent Applications | 125 |
| WIPO Patent Applications | 77 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 3 (2015-12-01) |
| Vendors | 56 |
Recent Clinical Trials for Plinabulin
| Title | Sponsor | Phase |
|---|---|---|
| First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC | Xiaorong Dong | Phase 2 |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | BeyondSpring Pharmaceuticals Inc. | Phase 2 |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | Merck Sharp & Dohme LLC | Phase 2 |
Clinical Trial Summary for Plinabulin
Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin
US Patents for Plinabulin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Plinabulin | ⤷ Try a Trial | Method of treating a brain tumor | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Try a Trial |
| Plinabulin | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Plinabulin | ⤷ Try a Trial | Nanoparticle formulations for delivering multiple therapeutic agents | AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown) | ⤷ Try a Trial |
| Plinabulin | ⤷ Try a Trial | Plinabulin compositions | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Try a Trial |
| Plinabulin | ⤷ Try a Trial | Method of treating cancer associated with a RAS mutation | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Try a Trial |
| Plinabulin | ⤷ Try a Trial | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | Duquesne University of the Holy Spirit (Pittsburgh, PA) | ⤷ Try a Trial |
| Plinabulin | ⤷ Try a Trial | Method of treating a brain tumor | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Plinabulin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Plinabulin | Australia | AU2016229295 | 2035-03-06 | ⤷ Try a Trial |
| Plinabulin | Australia | AU2021254549 | 2035-03-06 | ⤷ Try a Trial |
| Plinabulin | Brazil | BR112017018964 | 2035-03-06 | ⤷ Try a Trial |
| Plinabulin | Canada | CA2978679 | 2035-03-06 | ⤷ Try a Trial |
| Plinabulin | Chile | CL2017002242 | 2035-03-06 | ⤷ Try a Trial |
| Plinabulin | China | CN107530340 | 2035-03-06 | ⤷ Try a Trial |
| Plinabulin | European Patent Office | EP3265091 | 2035-03-06 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
